Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | SLC22A2 | O15244 | 7/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4200354 | 1.00 | LIPG (0.38) | LIPGCNR1CNR2SLC22A2CYP3A4 | |
| SCHEMBL4047791 | 0.92 | SLC22A2 (0.38) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL4197803 | 0.92 | SLC22A2 (0.38) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL4048441 | 0.92 | SLC22A2 (0.38) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL4199666 | 0.91 | SLC22A2 (0.38) | SLC22A2 | |
| SCHEMBL4049611 | 0.91 | SLC22A2 (0.39) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL4211772 | 0.91 | SLC22A2 (0.39) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL4195428 | 0.90 | SLC22A2 (0.38) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL4206599 | 0.90 | SLC22A2 (0.38) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL4196616 | 0.89 | SLC22A2 (0.37) | SLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476666-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-01-13 | — | — | US | claimed |
| US-20080015187-A1 | Hiv Integrase Inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-17 | — | — | US | claimed |
| US-7476666-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-20080015187-A1 | Hiv Integrase Inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015187-A1 | Hiv Integrase Inhibitors | REV1, ZC3HAV1, PNP | LIPG 4242/4885CNR1 2558/4885CNR2 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.